List Title | APhA DrugInfoLine

Focus on Lipids Care

SORT BY: Most Recent Most Viewed

February 5, 2018

Broader statin use reduces the risk of more cardiovascular events

READ

PREVIEW
When statin guidelines recommend use for primary prevention in a broader patient population, more atherosclerotic cardiovascular disease (ASCVD) events are prevented, according to a comparison of...
December 4, 2017

Statins are associated with development of diabetes in a high-risk population

READ

PREVIEW
Statin use was associated with an increased incidence of type 2 diabetes (T2D) in patients who were at high risk of developing diabetes, according to a 10-year analysis of data from the Diabetes...
September 5, 2017

Continuing statins after adverse reactions results in better outcomes

READ

PREVIEW
In patients who experienced an adverse reaction to their statin therapy, continuing treatment resulted in fewer cardiovascular (CV) events and deaths compared with patients who stopped treatment,...
April 24, 2017

Risk of CV events reduced with a PCSK9 inhibitor

READ

PREVIEW
Addition of evolocumab (Repatha—Amgen) to statin background therapy in patients with a history of atherosclerotic cardiovascular disease (ASCVD) resulted in significant reductions in LDL...
April 17, 2017

Statin intolerance increases risk of recurrent cardiac events

READ

PREVIEW
Statin intolerance in patients who have had a myocardial infarction (MI) resulted in an increased risk of recurrent MIs and coronary heart disease (CHD) events compared with patients who were...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.